ISO 18562 VOC Testing and Particle Testing (Medical Devices)
Overview
In medical device manufacturing, ensuring the safety and efficacy of products with breathing gas pathways is critical. Beyond standard mechanical functionality and structural durability, evaluating potential emissions of volatile organic compounds (VOCs) and airborne particles is vital for patient safety and global regulatory compliance. This is where the ISO 18562 standard series becomes essential.
Contact Us
Quick Summary for Regulatory Teams:
ISO 18562 establishes mandatory biological evaluation criteria for medical devices, components, and accessories that feature a breathing gas pathway (e.g., ventilators, CPAP machines, anesthesia workstations, and nebulizers). It quantifies particulate matter (ISO 18562-2), gas-phase organic emissions (ISO 18562-3), and leachables in condensate (ISO 18562-4) to prevent toxicological risks during patient ventilation.
What is ISO 18562?
ISO 18562 (EN ISO 18562) is a specialized series of biocompatibility standards designed to evaluate the emissions of volatile organic compounds (VOCs) and particulate matter from medical device gas pathways.
These emissions frequently arise from raw materials, manufacturing additives, cleaning agents, or chemical interactions occurring between the device’s interior surfaces and the gas stream delivered directly to the patient’s respiratory tract. If left unchecked, inhaled particulates or chemical vapors can cause pulmonary inflammation, systemic toxicity, or long-term organ damage.
Why VOC and Particle Testing Matters
Conducting thorough ISO 18562 testing protects patients, streamlines regulatory approvals, and reduces post-market liabilities:
Patient Safety: Because respiratory devices deliver air directly to patients’ lungs, any released particles or toxic VOCs bypass primary skin/mucosal defenses. ISO 18562 testing identifies and measures these potential hazards to verify exposure levels remain within safe toxicological limits.
Global Regulatory Compliance: Regulatory bodies such as the US FDA, US FDA QMSR, and EU MDR/IVDR notified bodies require complete ISO 18562 validation data alongside traditional ISO 10993 biological evaluations before market clearance.
Environmental and Operational Impact: Volatile organic compounds generated during device storage or operational heating can degrade internal materials or compromise clinical environments. Testing ensures device safety under worst-case operational parameters.
4 Key Components of ISO 18562 Testing Standards
The ISO 18562 standard framework consists of four primary parts, each addressing a distinct aspect of gas pathway biocompatibility evaluation:
ISO 18562-1 (General Principles & Risk Assessment): Outlines basic concepts, evaluation strategies, and overall risk management integration within the Biological Evaluation Plan (BEP).
ISO 18562-2 (Particulate Matter Testing): Specifies sampling methodologies and limits for airborne particulate matter released into the gas stream.
ISO 18562-3 (Volatile Organic Substances – VOC Emissions): Details sampling, thermal conditioning, and analytical testing methods (such as GC-MS) used to measure volatile organic compounds (VOCs), very volatile organic compounds (VVOCs), and semi-volatile organic compounds (SVOCs) released into the air stream.
ISO 18562-4 (Leachables in Condensate): Provides standardized protocols for evaluating liquid condensate formed within the gas pathway. It determines if water-soluble chemical leachables can migrate into liquid droplets and reach the patient’s airway.
Need direct clarity on testing protocols for your respiratory device
Connect with our regulatory experts today to structure a compliant testing strategy
Testing Methodologies of ISO 18562
Achieving compliance requires rigorous execution across a structured three-step laboratory methodology:
Sample Preparation & Conditioning: Medical devices are pre-conditioned under controlled environmental parameters (temperature, humidity, and flow rate) representing worst-case clinical usage conditions.
Emission Sampling: Ultra-pure air or gas is passed through the device gas pathway. Specialized particle counters or gravimetric filters capture particulate emissions (Part 2), while sorbent tubes trap volatile organic compounds (Part 3).
Chemical Analysis and Toxicological Reporting: Collected samples undergo high-precision analytical testing (GC-MS, LC-MS). Toxicologists calculate allowable daily exposure (ADE) limits to confirm chemical safety and verify adherence to safety thresholds.
Conclusion
In summary, adherence to the ISO 18562 standard series is essential for medical device manufacturers delivering products with breathing gas pathways. By validating particulate matter levels, chemical emissions, and condensate leachables across ISO 18562-1, 18562-2, 18562-3, and 18562-4, manufacturers ensure uncompromised patient safety, smooth market access, and complete environmental accountability.
How Operon Strategist Delivers ISO 18562 Compliance
Navigating gas pathway biocompatibility testing requires integrated engineering, quality management, and international regulatory experience. Operon Strategist provides end-to-end technical support to streamline your path to market approval:
Biological Evaluation Planning (BEP): Developing tailored risk management plans under ISO 18562-1, integrated directly with your overall Quality Management System (QMS) and Design History File (DHF).
Testing Protocol Architecture: Setting worst-case flow rate, temperature, and duration testing protocols required for ISO 18562-2 and ISO 18562-3 laboratory runs.
Global Regulatory Dossier Integration: Incorporating ISO 18562 test data seamlessly into US FDA (510(k), QMSR), CE Marking (EU MDR / IVDR), UKCA Marking, and CDSCO (India) submissions.
Engineering & Material Remediation: Providing expert engineering insights under New Product Design Development and Product Process Engineering for Manufacturing if toxicological tests show elevated VOC or particle levels.
Complete Turnkey Regulatory Strategy: Aligning device testing with global compliance needs, including SFDA (Saudi Arabia), ANVISA (Brazil), SAHPRA (South Africa), and Regulatory Due Diligence for Medical Devices.
Unsure if your device requires ISO 18562-4 condensate testing
Consult with Operon Strategist to audit your design pathway before lab testing
FAQ's
Which medical devices fall under the scope of ISO 18562?
Any medical device, component, or accessory containing a breathing gas pathway such as ventilators, CPAP units, anesthesia machines, oxygen concentrators, nebulizers, and breathing tubes must comply with ISO 18562.
How does ISO 18562 differ from ISO 10993 testing?
While ISO 10993 evaluates direct/indirect tissue and blood contact biocompatibility, ISO 18562 specifically assesses gas-phase biocompatibility for emissions (particles, VOCs, leachables) carried to the patient via a gas stream.
Is ISO 18562 testing mandatory for US FDA and EU MDR submissions?
Yes. Both the US FDA and EU MDR notified bodies strictly enforce ISO 18562 compliance data for all respiratory devices prior to granting market clearance.
What are the primary particle size limits under ISO 18562-2?
ISO 18562-2 sets allowable exposure thresholds for respirable fine particles and larger coarse dust, ensuring airborne debris released by the device does not harm patient lung tissue.
Can ISO 18562 testing be bypassed if biocompatible materials are used?
No. Material certification alone does not account for VOCs or particles generated during device assembly, heating, or gas-flow degradation. Physical testing of the finished device is required.